Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Advances in drug screening

With the discovery of suitable molecular targets - cellular molecules along pathways crucial for sustaining the life of cancer cells - comes the perplexing dilemma of where to find the next therapeutics that will bind to and disable those targets.

23 Oct 2007

Ubiquitin builds up an immune response

Ubiquitin is a small protein, which can be attached to other cellular proteins, a process known as ubiquitination.

22 Oct 2007

Is the spleen able to prohibit tumor cell proliferation?

Primary and metastatic tumors of the spleen are described as unusual, excluding involvement by lymphoma.

17 Oct 2007

Improvements in cancer survival in Northern Ireland

There have been improvements in cancer survival in Northern Ireland between 1993 and 2004, according to a new report from the Northern Ireland Cancer Registry (NICR), launched at Queen’s today.

4 Oct 2007

Daisy compound used to attack cancer stem cells

A new, easily ingested form of a compound that has already shown it can attack the roots of leukemia in laboratory studies is moving into human clinical trials, according to a new article by University of Rochester investigators in the journal, Blood.

2 Oct 2007

Novel strategy to tackle acute myelogenous leukemia

A novel strategy to hopefully beat into oblivion one of the most aggressive forms of acute myelogenous leukemia combines the strengths of some of the newest leukemia agents, researchers say.

25 Sep 2007

Re-engineered human T cells effectively target and kill cancerous B cells

Human white blood cells, engineered to recognize other malignant immune cells, could provide a novel therapy for patients with highly lethal B cell cancers such as acute lymphoblastic leukemia (ALL), according to researchers at Memorial Sloan-Kettering Cancer Center (MSKCC).

18 Sep 2007

Sexual function affected by stem cell transplant according to long-term study

A long-term study found that a type of stem cell transplant used for patients with life-threatening diseases, such as leukemia and lymphoma, results in decreased sexual function and activity for recipients.

18 Sep 2007

JAK genes and cancer

Cancer-causing genes can work in more powerful and sneaky ways than have been realized.

18 Sep 2007

Benefits and risks of breastfeeding

Extensive medical research shows that mothers' milk satisfies babies' nutritional needs far better than any manufactured infant formula.

17 Sep 2007

IMPACT: Increasing clinical trial participation

Before a new treatment for a disease like cancer becomes available, physician-researchers must recruit hundreds or thousands of patients to participate in clinical research trials.

14 Sep 2007

Vitamin C inhibits the growth of some tumors

Nearly 30 years after Nobel laureate Linus Pauling famously and controversially suggested that vitamin C supplements can prevent cancer, a team of Johns Hopkins scientists have shown that in mice at least, vitamin C - and potentially other antioxidants - can indeed inhibit the growth of some tumors ¯ just not in the manner suggested by years of investigation.

11 Sep 2007

Secondhand smoke affects pets too

The threat of secondhand smoke to the health of non-smokers has been known for years but now researchers say pets can also suffer from the effects of secondhand smoke.

5 Sep 2007

Secondhand smoke and pets

It has been in the news for years about how secondhand smoke is a health threat to nonsmokers. The Center for Disease Control and Prevention indicates that secondhand smoke is attributed with killing thousands of adult nonsmokers annually.

3 Sep 2007

Researchers discover what makes lymphomas tick

University of Pennsylvania researchers and their colleagues at the Wistar Institute and University of Oxford have discovered the molecular process by which the PAX5 protein, necessary for lymphocyte development, promotes the growth of common lymphomas, thereby unveiling a potential new target in the fight against cancer.

30 Aug 2007

Biologic treatment for rheumatoid arthritis and the risk of cancer

The relationship between rheumatoid arthritis (RA), an autoimmune disease marked by chronic inflammation of the joints and tissue surrounding vital organs, and the incidence of cancer is complicated.

30 Aug 2007

FDA grants orphan drug designation to TREANDA

Cephalon, Inc. announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for the company's investigational therapy, TREANDA (bendamustine HCl), for the treatment of chronic lymphocytic leukemia (CLL).

29 Aug 2007

Rapamycin study is first stage in development of new treatment

Rapamycin isn't your ordinary potential anti-cancer drug…It had a long and somewhat exotic history before undergoing preclinical (laboratory-based) studies at St. Jude as part of a national Pediatric Preclinical Testing Program (PPTP) investigation of its anticancer activity.

23 Aug 2007

Cancer stem cell scientists get $1.7 million to develop new leukemia drugs

"Modern cancer treatments fail to get to the root of the cancer - the stem cells - which is why many cancers recur despite aggressive treatment."

23 Aug 2007

Pharmion and MethylGene announce orphan drug designation for treatment of Hodgkin's lymphoma

Pharmion Corporation, along with its collaborator MethylGene Inc., today announced that the U.S. Food and Drug Administration (FDA) has designated the Companies' histone deacetylase (HDAC) inhibitor, MGCD0103, as an Orphan Drug for the treatment of Hodgkin's lymphoma in the United States.

21 Aug 2007